Companies TriSalus Life Sciences, Inc.
TriSalus Life Sciences (TLSI): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me TriSalus Life Sciences, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,692,830FY2023
- $4,136,595FY2024
- $4,823,349FY2025
CEO total pay was $4,823,349 in fiscal 2025, up from $4,136,595 in fiscal 2024.
FY2025: salary $600,920 · bonus $153,120 · stock awards $2,570,750 · option awards $1,482,762
Order TLSI
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Mary Szela | $600,920 | $153,120 | $2,570,750 | $1,482,762 | $0 | $0 | $15,797 | $4,823,349 |
| Chief Executive Officer and President | ||||||||
| David Patience | 268,462 | 239,188 | 1,136,750 | 1,721,549 | 0 | 0 | 77,679 | 3,443,628 |
| Chief Financial Officer | ||||||||
| Richard Marshak | 435,329 | 113,535 | 399,250 | 592,280 | 0 | 0 | 15,606 | 1,556,000 |
| Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Mary Szela | $4,823,349 | $4,136,595 | $2,692,830 | ↑ +686,754 |
| David Patience | 3,443,628 | — | — | — |
| Richard Marshak | 1,556,000 | 1,365,569 | — | ↑ +190,431 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
TriSalus' executive compensation program is designed to attract, retain and motivate individuals with superior ability, experience and leadership capability to deliver on annual and long-term business objectives necessary to create stockholder value. The program uses a mix of base salary, annual performance-based cash bonuses, and equity-based incentive awards (options, RSUs, and PSUs) to align the interests of executive officers with those of stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Richard Marshak | RSU | 955 | — | $6,666 |
| Richard Marshak | RSU | 1,032 | — | 7,203 |
| Richard Marshak | Option | 2,974 | 10.3 | — |
| Richard Marshak | RSU | 5,156 | — | 35,989 |
| Mary Szela | RSU | 9,193 | — | 64,167 |
| Richard Marshak | RSU | 11,063 | — | 77,220 |
| Richard Marshak | RSU | 12,500 | — | 87,250 |
| Richard Marshak | Option | 16,667 | 12 | — |
| Mary Szela | RSU | 17,302 | — | 0 |
| Mary Szela | Option | 18,536 | 2.43 | — |
| Mary Szela | Option | 20,689 | 10.3 | — |
| Richard Marshak | Option | 20,834 | 9.28 | — |
| Mary Szela | RSU | 21,089 | — | 147,201 |
| Richard Marshak | Option | 30,078 | 4.01 | — |
| Richard Marshak | Option | 34,531 | 9.5 | — |
| Mary Szela | RSU | 40,000 | — | 279,200 |
| Richard Marshak | RSU | 60,000 | — | 418,800 |
| Mary Szela | RSU | 63,674 | — | 444,445 |
| David Patience | RSU | 65,000 | — | 453,700 |
| Mary Szela | Option | 71,875 | 11.51 | — |
| Richard Marshak | Option | 75,000 | 5.3 | — |
| Mary Szela | RSU | 101,345 | — | 0 |
| Richard Marshak | Option | 120,000 | 5.55 | — |
| Mary Szela | RSU | 125,000 | — | 872,500 |
| David Patience | Option | 130,000 | 5.55 | — |
| Mary Szela | Option | 156,406 | 9.4 | — |
| David Patience | RSU | 200,000 | — | 1,396,000 |
| Mary Szela | Option | 240,000 | 5.3 | — |
| Mary Szela | Option | 250,000 | 5.55 | — |
| David Patience | Option | 290,000 | 3.88 | — |
| Mary Szela | RSU | 300,000 | — | 2,094,000 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| William ValleIndependent · Compensation (Chair) · Audit · Science and Technology | $83,750 | $0 | $156,960 | — | — | $240,710 |
| Gary GordonIndependent · Compensation · Science and Technology (Chair) | 63,125 | 0 | 156,960 | — | — | 220,085 |
| Mats WahlströmIndependent · Board Chair · Compensation · Nominating and Corporate Governance | 95,000 | 0 | 43,749 | — | — | 138,749 |
| David J. MatlinIndependent · Nominating and Corporate Governance · Audit (Chair) | 35,000 | 49,999 | 43,749 | — | — | 128,748 |
| Arjun DesaiIndependent · Departed during FY | 83,750 | 0 | 43,749 | — | — | 127,499 |
| Sean MurphyNot independent · Departed during FY | 0 | 74,999 | 43,749 | — | — | 118,748 |
| Kerry HicksIndependent · Nominating and Corporate Governance · Audit | 72,500 | 0 | 43,749 | — | — | 116,249 |
| Liselotte HyveledIndependent · Departed during FY | 4,409 | 49,999 | 0 | — | — | 54,408 |
| Andrew von EschenbachIndependent · Not standing for re-election | 37,170 | 0 | 0 | — | — | 37,170 |
| George Kelly MartinIndependent · Departed during FY | 23,984 | 0 | 0 | — | — | 23,984 |
| Mary SzelaEmployee director | — | — | — | — | — | 0 |
| Michael P. StanskyIndependent · Audit Committee · Compensation Committee · Science and Technology Committee (Chair) · Newly elected | — | — | — | — | — | — |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 15,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $498,688 |
| Equity awards (grant-date value) | $174,997 |
| All other compensation | $0 |
| Total cost of the board | $673,685 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names TriSalus Life Sciences as a peer
Companies that benchmark against TLSI
No companies currently name TLSI as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | TriSalus Life Sciences, Inc. | 2025 | Mary Szela | $600,920 | $2,570,750 | $1,482,762 | $0 | $4,823,349 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-14 | 32,625,082 | 1,206,105 | 176,369 | 96.43% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-14 | 96.43%a |
a. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (19 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Mary Szela. DEF 14A, filed 2026-03-31. Section “Summary Compensation Table” · page 31. As printed: 4,823,349. View filing ↗
- Section 01, David Patience. DEF 14A, filed 2026-03-31. Section “Summary Compensation Table” · page 31. As printed: 3,443,628. View filing ↗
- Section 01, Richard Marshak. DEF 14A, filed 2026-03-31. Section “Summary Compensation Table” · page 31. As printed: 1,556,000. View filing ↗
- Section 08, William Valle. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 240,710. View filing ↗
- Section 08, Gary Gordon. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 220,085. View filing ↗
- Section 08, Mats Wahlström. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 138,749. View filing ↗
- Section 08, David J. Matlin. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 128,748. View filing ↗
- Section 08, Arjun Desai. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 127,499. View filing ↗
- Section 08, Sean Murphy. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 118,748. View filing ↗
- Section 08, Kerry Hicks. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 116,249. View filing ↗
- Section 08, Liselotte Hyveled. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 54,408. View filing ↗
- Section 08, Andrew von Eschenbach. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 37,170. View filing ↗
- Section 08, George Kelly Martin. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 23,984. View filing ↗
- Section 08, Mary Szela. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Michael P. Stansky. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: —. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-14. Item 5.07 · say-on-pay result. As reported: 96.43% (votes for as printed: 32,625,082). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 498,688 + equity 174,997 + all other 0 = 673,685, summed across the director compensation table rows.
- TriSalus Life Sciences, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-03-31. CEO total compensation as printed in TriSalus Life Sciences, Inc.'s own proxy. As printed: 4,823,349. View filing ↗